cyc 202 has been researched along with purvalanol a in 28 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (purvalanol a) | Trials (purvalanol a) | Recent Studies (post-2010) (purvalanol a) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 86 | 0 | 42 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ducrot, P; Endicott, J; Grierson, DS; Legraverend, M; Leost, M; Ludwig, O; Meijer, L; Noble, M; Tunnah, P | 1 |
| Matter, H; Naumann, T | 1 |
| Havlícek, L; Krystof, V; Kuzma, M; Lenobel, R; Strnad, M | 1 |
| Bhattacharjee, AK; Ellis, W; Gerena, L; Geyer, JA; Kathcart, AK; Kyle, DE; Li, Z; Lopez-Sanchez, M; Nichols, DA; Prigge, ST; Terrell, J; Waters, NC; Woodard, CL | 1 |
| Fuksová, K; Hanus, J; Havlícek, L; Krystof, V; Kuzma, M; Lenobel, R; Moravcová, D; Moravec, J; Otyepka, M; Strnad, M | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Bernard, P; Bettayeb, K; Colas, P; Ferandin, Y; Fournet, G; Joseph, B; Lamigeon, C; Mateo-Lozano, S; Meijer, L; Notario, V; Popowycz, F; Schneider, C; Tirado, OM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Abdellah, FN; Demange, L; Ferandin, Y; Galons, H; Gresh, N; Lozach, O; Meijer, L | 1 |
| Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Daikoku, T; Fujita, M; Isomura, H; Kiyono, T; Kudoh, A; Nishiyama, Y; Sugaya, Y; Tsurumi, T | 1 |
| Fischer, PM; Goddard, PM; Lane, DP; Nutley, BP; Raynaud, FI; Workman, P | 1 |
| Beaman-Hall, CM; Mathur, A; Monaco, EA; Vallano, ML | 1 |
| Indorato, RL; Lacroix, F; Margolis, RL; Panopoulos, A; Skoufias, DA | 1 |
| An, R; Hagiya, Y; Ishikawa, T; Li, S; Saito, H; Tamura, A; Tokushima, D | 1 |
| Arısan, ED; Çoker, A; Palavan-Ünsal, N | 1 |
| Chen, Y; Tsai, YH; Tseng, SH | 1 |
| Agostinelli, E; Arisan, ED; Calcabrini, A; Coker-Gurkan, A; Obakan, P; Unsal, NP | 1 |
| Ceckova, M; Cihalova, D; Hofman, J; Staud, F | 1 |
| Arisan, ED; Coker-Gurkan, A; Guvenir, E; Obakan, P; Unsal, NP | 1 |
| Ceckova, M; Hofman, J; Klimes, J; Kučera, R; Neumanova, Z; Staud, F | 1 |
| Arisan, ED; Berrak, O; Coker-Gürkan, A; Obakan-Yerlikaya, P; Palavan-Unsal, N | 1 |
| Arisan, ED; Coker-Gurkan, A; Obakan-Yerlikaya, P; Ozfiliz-Kilbas, P; Palavan-Unsal, N; Sarikaya, B; Temizci, B | 1 |
| Büküm, N; Flaxová, M; Hofman, J; Kouklíková, E; Louvarová, D; Novotná, E; Wsól, V | 1 |
| Encheva, V; Heesom, KJ; Lach, R; Ray, S; Reddy, AB; Snijders, AP; Valekunja, UK | 1 |
1 review(s) available for cyc 202 and purvalanol a
| Article | Year |
|---|---|
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2018 |
27 other study(ies) available for cyc 202 and purvalanol a
| Article | Year |
|---|---|
Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
Topics: Adenine; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Crystallography, X-Ray; Cyclin B; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Protein Serine-Threonine Kinases; Purines; Roscovitine; Structure-Activity Relationship | 2000 |
Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.
Topics: Binding Sites; Crystallography, X-Ray; Cyclin-Dependent Kinases; Enzyme Inhibitors; Ligands; Models, Molecular; Molecular Structure; Purines; Quantitative Structure-Activity Relationship | 2002 |
Synthesis and biological activity of olomoucine II.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC28 Protein Kinase, S cerevisiae; Cell Survival; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Kinetin; Purines; Roscovitine; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
Topics: Amino Acid Sequence; Animals; Antimalarials; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Molecular Sequence Data; Plasmodium falciparum; Structure-Activity Relationship | 2003 |
2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Protein Binding; Purines; Roscovitine; Structure-Activity Relationship | 2003 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Humans; Male; Mice; Mice, Nude; Purines; Pyrazoles; Roscovitine; Triazines | 2009 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 5; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Roscovitine; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.
Topics: Cell Line; Cyclin-Dependent Kinases; Enzyme Inhibitors; HeLa Cells; Herpesvirus 4, Human; Humans; Immediate-Early Proteins; Purines; Roscovitine; S Phase; Viral Proteins; Virus Replication | 2004 |
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.
Topics: Animals; Area Under Curve; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Free Radicals; Gene Library; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Purines; Roscovitine; Structure-Activity Relationship; Time Factors | 2004 |
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Topics: 4-Butyrolactone; Animals; Apoptosis; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cerebellum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinases; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Kinetin; Mitogen-Activated Protein Kinases; Neurons; Phosphorylation; Proto-Oncogene Proteins; Purines; Pyrimidines; Rats; Rats, Sprague-Dawley; Roscovitine; Signal Transduction; Sulfonamides | 2004 |
Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed.
Topics: 2-Aminopurine; CDC2 Protein Kinase; Coloring Agents; Cysteine Proteinase Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique, Indirect; Fluorescent Dyes; HCT116 Cells; HeLa Cells; Humans; Hydrolysis; Lactams; Leupeptins; Mitosis; Phosphoprotein Phosphatases; Propidium; Protein Kinase Inhibitors; Purines; Roscovitine | 2007 |
Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Membrane; Cell Survival; Chlorophyll; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Hematoporphyrins; Humans; Kinetin; Models, Molecular; Molecular Conformation; Molecular Structure; Neoplasm Proteins; Photosensitizing Agents; Protein Kinase Inhibitors; Purines; Quantitative Structure-Activity Relationship; Quinazolines; Roscovitine; Spodoptera; Transfection | 2009 |
Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.
Topics: Acetyltransferases; Apoptosis; Caco-2 Cells; Caspase 3; Caspase 9; Colonic Neoplasms; Cyclin-Dependent Kinases; Humans; Membrane Potential, Mitochondrial; Polyamines; Protein Kinase Inhibitors; Purines; Putrescine; RNA Interference; RNA, Small Interfering; Roscovitine; Spermine | 2012 |
Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; CDC2 Protein Kinase; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Down-Regulation; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; MicroRNAs; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Purines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Survivin | 2013 |
CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Male; Mitochondria; Polyamines; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Receptors, Androgen; Roscovitine | 2014 |
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line; Cell Membrane; Cell Proliferation; Cyclin-Dependent Kinases; Daunorubicin; Drug Synergism; Gene Expression Regulation; Humans; Protein Kinase Inhibitors; Purines; RNA, Messenger; Roscovitine | 2013 |
Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; bcl-2-Associated X Protein; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinases; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunoprecipitation; Membrane Potential, Mitochondrial; Methylcholanthrene; Purines; Roscovitine; Tumor Cells, Cultured | 2014 |
Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
Topics: Adenosine Triphosphate; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Chromatography, High Pressure Liquid; Female; Maternal Exposure; Multidrug Resistance-Associated Proteins; Placenta; Pregnancy; Pregnancy, Animal; Purines; Rats; Rats, Wistar; Roscovitine; Trophoblasts; Xenobiotics | 2016 |
mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Topics: Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Receptors, Androgen; Roscovitine; Signal Transduction; TOR Serine-Threonine Kinases | 2016 |
Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells.
Topics: Adenine; Autophagy; Cell Proliferation; Cell Survival; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Protein Kinase Inhibitors; Purines; Reactive Oxygen Species; Roscovitine; Time Factors; Unfolded Protein Response; Uterine Cervical Neoplasms | 2018 |
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Topics: Aldo-Keto Reductase Family 1 Member C3; Anthracyclines; Antineoplastic Agents; Cloning, Molecular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HCT116 Cells; Hep G2 Cells; Humans; Neoplasms; Purines; Roscovitine | 2018 |
Phenotypic proteomic profiling identifies a landscape of targets for circadian clock-modulating compounds.
Topics: Adenine; Anthracenes; Cell Line, Tumor; Circadian Clocks; Circadian Rhythm; Drug Evaluation, Preclinical; Humans; Phenotype; Phosphorylation; Proteomics; Purines; Roscovitine; Signal Transduction; Transcription Factors | 2019 |